Axinn partner Chad Landmon was named to The National Law Journal’s 2020 list of Healthcare/Life Sciences Trailblazers. Chad was recognized as a professional who has helped to open up generic competition, providing significant cost savings to consumers. The complete list of “trailblazers” is featured in a special supplement published in The National Law Journal.
When Chad first became involved in intellectual property work for generic pharmaceutical clients 20 years ago, he quickly realized that these companies often had FDA issues. By coupling his patent litigation experience with his FDA expertise, Chad enables life sciences clients to develop and execute on patent and FDA strategies to bring products to market in the most efficient and profitable manner. During the course of his career, Chad was involved in helping to bring to market eight of the top 10 generic drugs as ranked by 2018 cost savings and nearly half of the top 100 generic drugs sold in 2018.